Table 1.
Sleep metrics derived from polysomnography
| Placebo (STD) | Dexmedetomidine (STD) | Diff (95% CI) | P value | |
|---|---|---|---|---|
| Total dark time (mins) | 600 (0.3) | 600 (0.4) | 0.1 (−0.5, 0.2) | 0.422 |
| Total sleep time (mins) | 523 (40) | 544 (33) | −16 (−43, 11) | 0.207 |
| Sleep Efficiency (%) | 87 (7) | 91 (5) | −3 (−7, 2) | 0.211 |
| WASO (mins) | 53 (39) | 42 (29) | 5 (−19, 29) | 0.639 |
| Wake duration (min) | 77 (40) | 56 (33) | 16 (−11, 43) | 0.212 |
| N1 (mins) | 24 (13) | 24 (19) | 0.3 (−10, 11) | 0.953 |
| N2 (mins) | 256 (46) | 326 (69) | −63 (−107, −19) | 0.010 |
| N3 (mins) | 122 (32) | 108 (34) | 5 (−7, 18) | 0.362 |
| REM (mins) | 120 (27) | 86 (53) | 42 (5, 78) | 0.031 |
| N1 TST (%) | 5 (3) | 5 (4) | 0.2 (−2, 2) | 0.881 |
| N2 TST (%) | 49 (6) | 60 (11) | −10 (−16, −4) | 0.005 |
| N3 TST (%) | 24 (6) | 20 (6) | 2 (−0.2, 4) | 0.071 |
| REM TST (%) | 23 (6) | 16 (11) | 8 (1, 15) | 0.026 |
WASO, wake after sleep onset; N1, non-rapid eye movement stage 1; N2, non-rapid eye movement stage 2; N3, non-rapid eye movement stage 3; REM, rapid eye movement stage; TST, total sleep time. Diff, differences in the mean of the groups.